Catalent has partnered up with Supernus Pharmaceuticals to supply the generics maker's extended-release epilepsy drug, a product the companies say has a chance to snag a share of a big market.
Shares of Supernus Pharmaceuticals rocketed up more than 100% yesterday as word spread that the FDA had provided a tentative approval for its extended-release version of the generic epilepsy drug Topamax.
Supernus Pharmaceuticals came out of the IPO gate this morning, pricing its shares at a hefty discount in order to complete its long-planned effort to go public.
Supernus Pharmaceuticals has finally dusted off the paperwork and suggested a $12 to $14 price range on some 5.8 million shares.
Rockville, MD-based Supernus has raised $35 million from an unnamed drug development partner. Supernus sold the future royalties from a new product it will help the partner develop. And that brings